Erasca

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company employs an artificial intelligence drug discovery platform known as OPRA, which utilizes machine learning to analyze large-scale data sets and identify novel tumor biology, thereby accelerating drug development. Erasca is developing a pipeline of oncology drugs, including Naporafenib, an innovative pan-RAF inhibitor aimed at treating NRAS-mutant melanoma and other RAS/MAPK-driven tumors. Additionally, the company is advancing ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, targeting key nodes in the RAS/MAPK signaling pathway. Through its research and collaborations, Erasca aims to provide precision oncology options that offer potential solutions for treating and possibly curing cancer.